

DAFTAR PUSTAKA

- Adiarto, S. (2012). Rokok, Perokok Pasif, Kematian Kardiovaskular dan Jaminan Kesehatan. *Jurnal Kardiologi Indonesia*, 3(3). <https://doi.org/https://doi.org/10.30701/ijc.v33i3.41>
- Aberg, J.A., Lacy, C.F., Amstrong, L.L., Goldman, M.P., dan Lance, L.L. (2009). Drug Information Handbook, 17th edition, Lexi-Comp for the American Pharmacist Association
- Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012). Oral Anticoagulant Therapy - Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*, 141(2), e44S-e88S. <https://doi.org/10.1378/chest.11-2292>
- Agustin, O. A., & Fitriyaningsih, F. (2021). Agustin, O. A., & Fitriyaningsih, F. (2020). Kajian Interaksi Obat Berdasarkan Kategori Signifikansi Klinis Terhadap Pola Peresepan Pasien Rawat Jalan Di Apotek X Jambi. *Electronic Journal Scientific of Environmental Health And Disease*, 1(1). <https://doi.org/10.22437/esehad.v1i1.10759>
- Agustini, T., Arifin, H., Hanif A. (2016). Perbandingan Dosis Warfarin terhadap Durasi Tercapainya Target INR pada Pasien CHF dengan Atrial Fibrillation. *Jurnal Sains Farmasi dan Klinis*. Ikatan Apoteker Indonesia, Sumatera Barat.
- Ahmad S. (1991). Omeprazole-Warfarin Interaction. *South Med J*. 84(5):674-675. [PubMed 2035104]
- Akin F, Yaylali GF, Bastemir M, et al. (2008). Effect of Methimazole on Warfarin Anticoagulation in A Case of Graves' Disease. *Blood Coagul Fibrinolysis*. 19(1):89-91. [PubMed 18180622]
- Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., & Palareti, G. (2008a). Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*, 133(6), 160S-198S. <https://doi.org/10.1378/chest.08-0670>
- Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., & Palareti, G. (2008b). Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*, 133(6), 160S-198S. <https://doi.org/10.1378/chest.08-0670>
- Badan Penelitian dan Pengembangan Kesehatan. (2018). *Laporan Nasional RISKESDAS 2018*. <https://repository.badankebijakan.kemkes.go.id/id/eprint/3514/>

- Barry M, Feely J. (1990). Allopurinol Influences Aminophenazone Elimination. *Clin Pharmacokinet.* 19(2):167-169. [PubMed 2379382]
- Bax ND, Lennard MS, Tucker GT, et al. (1984). The Effect of Beta-Adrenoceptor Antagonists on The Pharmacokinetics and Pharmacodynamics of Warfarin After A Single Dose. *Br J Clin Pharmacol.* 17(5):553-557. [PubMed 6329253]
- Bertram, V., Yeo, K., Anoopkumar-Dukie, S., & Bernaitis, N. (2019). Proton Pump Inhibitors Co-Prescribed with Warfarin Reduce Warfarin Control as Measured by Time in Therapeutic Range. *International Journal of Clinical Practice*, 73(11). <https://doi.org/10.1111/ijcp.13382>
- Brouwers, J. R. B. J., & De Smet, P. A. C. (1994). Pharmacokinetic-Pharmacodynamic Drug Interactions with Nonsteroidal Anti-Inflammatory Drugs. Dalam *PHARMACOKINETIC DRUG INTERACTIONS Clin. Pharmacokinet* (Vol. 27, Nomor 6).
- Burroughs SF, Johnson GJ. (1990). Beta-Lactam Antibiotic-Induced Platelet Dysfunction: Evidence for Irreversible Inhibition of Platelet Activation In Vitro and In Vivo after Prolonged Exposure to Penicillin. *Blood.* 75(7):1473-1480. [PubMed 2180496]
- Buttigieg, S. C., Abela, L., & Pace, A. (2018). Variables Affecting Hospital Length of Stay: A Scoping Review. Dalam *Journal of Health Organization and Management* (Vol. 32, Nomor 3, hlm. 463–493). Emerald Publishing. <https://doi.org/10.1108/jhom-10-2017-0275>
- Center for Disease Control and Prevention (CDC), 2024, Data and Statistics on Venous Thromboembolism. United States. Diakses pada 10 September 2024 melalui <https://www.cdc.gov/blood-clots/data-research/facts-stats/index.html#:~:text=The%20risk%20is%20greatest%20in%20the%20first%20of%20pregnancy%20childbirth%20or%20the%203-month%20period%20after%20delivery.>
- Chai-Adisaksopha, C., Hillis, C., Isayama, T., Lim, W., Iorio, A., & Crowther, M. (2015). Mortality Outcomes in Patients Receiving Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Journal of Thrombosis and Haemostasis*, 13(11), 2012–2020. <https://doi.org/10.1111/jth.13139>
- Chesebro JH, Fuster V, Elveback LR, et al. (1983). Trial of Combined Warfarin Plus Dipyridamole or Aspirin Therapy in Prosthetic Heart Valve Replacement: Danger of Aspirin Compared with Dipyridamole. *Am J Cardiol.* 51(9):1537-1541. [PubMed 6342354]
- Clark, M.A., Finkel, R., Rey, J.A., Whalen, K. (2012). Lippincott's Illustrated Reviews, Wolters Kluwer Health/Lippincott Williams & Wilkins, Baltimore.

- Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., Wang, S., Alings, M., Xavier, D., Zhu, J., Diaz, R., Lewis, B. S., Darius, H., Diener, H.-C., Joyner, C. D., ... RE-LY Steering Committee and Investigators. (2009). Dabigatran versus Warfarin in Patients with Atrial Fibrillation. *New England Journal of Medicine*, *361*(12), 1139–1151. <https://doi.org/10.1056/nejmoa0905561>
- DiPiro, J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Wells, B. G., & Michael Posey, L. (2014). *Pharmacotherapy: A Pathophysiologic Approach* (7 ed.). The McGraw Hill Companies Inc.
- Dowd, M. B., Vavra, K. A., Witt, D. M., Delate, T., & Martinez, K. (2011). Empiric Warfarin Dose Adjustment with Prednisone Therapy. A Randomized, Controlled Trial. *Journal Of Thrombosis And Thrombolysis*, *31*(4), 472–477. <https://doi.org/10.1007/s11239-010-0535-8>
- Friberg, L., Rosenqvist, M., Lindgren, A., Terént, A., Norrving, B. and Asplund, K. (2014). High Prevalence of Atrial Fibrillation Among Patients with Ischemic Stroke. *Stroke*, *45*(9), pp.2599-2605.
- Furdiyanti, N. H., Pramantara, I. D. P., & Wahyono, D. (2014). Evaluasi Dosis Warfarin dan Hasil Terapinya pada Pasien Rawat Jalan. *Jurnal Manajemen dan Pelayanan Farmasi (Journal of Management and Pharmacy Practice)*, *4*(3), 175–179. <https://doi.org/https://doi.org/10.22146/jmpf.284>
- Garrison, S.R., Green, L., Kolber, M.R., Korownyk, C.S., Olivier, N.M., Heran, B.S., Flesher, M.E. and Allan, G.M. (2020). The Effect of Warfarin Administration Time on Anticoagulation Stability (Inrange): A Pragmatic Randomized Controlled Trial. *The Annals of Family Medicine*, *18*(1), pp.42-49.
- Ghaswalla, P. K., Harpe, S. E., Tassone, D., & Slattum, P. W. (2012). Warfarin-Antibiotic Interactions in Older Adults of An Outpatient Anticoagulation Clinic. *American Journal of Geriatric Pharmacotherapy*, *10*(6), 352–360. <https://doi.org/10.1016/j.amjopharm.2012.09.006>
- Gherasim, L. (2022). Association of Atrial Fibrillation with Diabetes Mellitus, High Risk Comorbidities. *Maedica*, *17*(1), p.143.
- Gitawati, R. (2008). Interaksi Obat dan Beberapa Implikasinya, *Media Penelitian dan Pengembangan Kesehatan*, **18** (4 Des).
- Gómez-Outes, A., Terleira-Fernández, A. I., Calvo-Rojas, G., Suárez-Gea, M. L., & Vargas-Castrillón, E. (2013). Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups. *Thrombosis*, *2013*(1), 640723. <https://doi.org/10.1155/2013/640723>

- Gotta AW, Sullivan CA, Seaman J, et al. (1972). Prolonged Intraoperative Bleeding Caused by Propylthiouracil-Induced Hypoprothrombinemia. *Anesthesiology*. 37:562-563. [PubMed 5079309]
- Hansen, P. W., Sehested, T. S. G., Fosbøl, E. L., Torp-Pedersen, C., Køber, L., Andersson, C., & Gislason, G. H. (2018). Trends in Warfarin Use and Its Associations with Thromboembolic and Bleeding Rates in A Population With Atrial Fibrillation Between 1996 and 2011. *PLoS ONE*, 13(3). <https://doi.org/10.1371/journal.pone.0194295>
- Hata, M., Shiono, M., Akiyama, K., Sezai, A., Wakui, S., Kimura, H., & Sekino, H. (2014). Incidence of Drug Interaction When Using Proton Pump Inhibitor and Warfarin According to Cytochrome P450 2C19 (CYP2C19) Genotype in Japanese. *Thoracic and Cardiovascular Surgeon*, 63(1), 45–50. <https://doi.org/10.1055/s-0034-1383814>
- Hazlewood, K. A., Fugate, S. E., & Harrison, D. L. (2006). Effect of Oral Corticosteroids on Chronic Warfarin Therapy. Dalam *Annals of Pharmacotherapy* (Vol. 40, Nomor 12, hlm. 2101–2106). <https://doi.org/10.1345/aph.1H418>
- Hickmott H, Wynne H, Kamali F. (2003). The Effect of Simvastatin Co-Medication on Warfarin Anticoagulation Response and Dose Requirements. *Thromb Haemost.* 89(5):949-950. [PubMed 12719797]
- Hindricks, G., Potpara, T., Kirchhof, P., Kühne, M., Ahlsson, A., Balsam, P., Bauersachs, J., Benussi, S., Brandes, A., Braunschweig, F., Camm, A. J., Capodanno, D., Casadei, B., Conen, D., Crijns, H. J. G. M., Delgado, V., Dobrev, D., Drexel, H., Fitzsimons, D., ... Zakirov, N. U. (2021). 2020 ESC Guidelines for The Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with The European Association for Cardio-Thoracic Surgery (EACTS). Dalam *European Heart Journal* (Vol. 42, Nomor 5, hlm. 373–498). Oxford University Press. <https://doi.org/10.1093/eurheartj/ehaa612>
- Howard-Thompson, A., Luckey, A., George, C., Choby, B. A., & Self, T. H. (2014). Graves' Disease and Treatment Effects on Warfarin Anticoagulation. *Case Reports in Medicine*, 2014. <https://doi.org/10.1155/2014/292468>
- Juurlink, D. N. (2007). Drug Interactions with Warfarin: What Clinicians Need to Know. *CMAJ. Canadian Medical Association Journal*, 177(4), 369–371. <https://doi.org/10.1503/cmaj.070946>
- Karunarathna, I., Gunasena, P., Jayawardana, A., Gunathilaka, S., Ekanayake, U., De Silva, M., & Rajapaksha, S. (2005). Mechanism of Action, and Clinical Considerations in the Management of Thromboembolic Disorders. *Anuradhapura Clinical Journal / Comprehensive Review of Warfarin: Indications*. <https://doi.org/10.13140/RG.2.2.34669.81126>

- Khan, F., Tritschler, T., Kahn, S. R., & Rodger, M. A. (2021). Venous Thromboembolism. Dalam *The Lancet* (Vol. 398, Nomor 10294, hlm. 64–77). Elsevier B.V. [https://doi.org/10.1016/S0140-6736\(20\)32658-1](https://doi.org/10.1016/S0140-6736(20)32658-1)
- Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H. C., Heidbuchel, H., Hendriks, J., Hindricks, G., Manolis, A. S., Oldgren, J., Popescu, B. A., Schotten, U., Van Putte, B., Vardas, P., Agewall, S., Camm, J., Duncan, E. (2016). 2016 ESC Guidelines for The Management of Atrial Fibrillation Developed in Collaboration with EACTS. Dalam *European Heart Journal* (Vol. 37, Nomor 38). Oxford University Press. <https://doi.org/10.1093/eurheartj/ehw210>
- Laredo, M., Waldmann, V., Khairy, P., & Nattel, S. (2018). Age as a Critical Determinant of Atrial Fibrillation: A Two-sided Relationship. Dalam *Canadian Journal of Cardiology* (Vol. 34, Nomor 11, hlm. 1396–1406). Elsevier Inc. <https://doi.org/10.1016/j.cjca.2018.08.007>
- Lwanga, S. K., & Lemeshow, S. (1991). *Sample Size Determination in Health Studies: A Practical Manual*. World Health Organization. https://apps.who.int/iris/handle/10665/40062?locale-attribute=zh&utm_source=transaction&utm_medium=email
- Malhotra, K., Ishfaq, M. F., Goyal, N., Katsanos, A. H., Parissis, J., Alexandrov, A. W., Alexandrov, A. V., & Tsivgoulis, G. (2019). Oral Anticoagulation in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis. *Neurology*, 92(21), e2421–e2431. <https://doi.org/10.1212/WNL.0000000000007534>
- Mazurek, M., Huisman, M.V., Rothman, K.J., Paquette, M., Teutsch, C., Diener, H.C., Dubner, S.J., Halperin, J.L., Zint, K., Franca, L.R. and Lu, S. (2018). Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program. *The American Journal of Medicine*, 131(8), pp.945-955.
- McCall, K. L., Anderson, H. G., & Jones, A. D. (2004). Determination of The Lack of A Drug Interaction between Azithromycin and Warfarin. *Pharmacotherapy*, 24(2 I), 188–194. <https://doi.org/10.1592/phco.24.2.188.33148>
- McDonald, M. G., Au, N. T., Wittkowsky, A. K., & Rettie, A. E. (2012). Warfarin-Amiodarone Drug-Drug Interactions: Determination of [I]u/K I,u for Amiodarone and Its Plasma Metabolites. *Clinical Pharmacology and Therapeutics*, 91(4), 709–717. <https://doi.org/10.1038/clpt.2011.283>
- Megawati, S., Lestari, T., & Setyani, W. L. (2019). Evaluasi Penggunaan Warfarin Oral Terhadap Nilai INR Pasien Jantung Rawat Jalan RSU Kabupaten Tangerang 2018. *Jurnal Farmagazine*, 6(2), 10–17. <https://doi.org/10.47653/farm.v6i2.140>
- Nagata, N., Niikura, R., Aoki, T., Sakurai, T., Moriyasu, S., Shimbo, T., Sekine, K., Okubo, H., Watanabe, K., Yokoi, C., Yanase, M., Akiyama, J., & Uemura, N.

- (2015). Effect of Proton-Pump Inhibitors on The Risk of Lower Gastrointestinal Bleeding Associated with Nsaids, Aspirin, Clopidogrel, and Warfarin. *Journal of Gastroenterology*, 50(11), 1079–1086. <https://doi.org/10.1007/s00535-015-1055-2>
- Nam, Y. H., Han, X., Brensinger, C. M., Bilker, W. B., Leonard, C. E., & Hennessy, S. (2020). Sulfonylureas and Metformin Were Not Associated with An Increased Rate of Serious Bleeding in Warfarin Users: A Self-Controlled Case Series Study. *Clinical Pharmacology and Therapeutics*, 108(5), 1010–1017. <https://doi.org/10.1002/cpt.1885>
- NCBI. (2024). *PubChem Compound Summary for CID 54678486*, Warfarin. National Institute of Health. <https://pubchem.ncbi.nlm.nih.gov/compound/Warfarin>
- Nuraeni, I. (2021). *Profil Penggunaan Warfarin pada Pasien Rawat Jalan di Rumah Sakit Akademik Universitas Gadjah Mada*. Universitas Gadjah Mada.
- O'Reilly RA. (1980). Spironolactone and Warfarin Interaction. *Clin Pharmacol Ther*. 27(2):198-201. [PubMed 7353340]
- Pagano, M. B., Chandler, W. L., Sam, C. M. E (2012). Bleeding Risks and Response to Therapy in Patients with INR Higher than 9. *Am J Pathol*, 138: 546-550.
- Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., Becker, R. C., Nessel, C. C., Paolini, J. F., Berkowitz, S. D., Fox, K. A. A., Califf, R. M., & Rocket AF Steering Committee. (2011). Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. *New England Journal of Medicine*, 365(10), 883–891. <https://doi.org/10.1056/NEJMoA1009638>
- Petretich DA. (1990). Reversal of Osmolite-Warfarin Interaction by Changing Warfarin Administration Time. *Clin Pharm*. 9(2):93. [PubMed 2106407]
- Porter eld LM. (2000). Why did the response to warfarin change? *RN*. 63(12);107. [PubMed 11151821]
- Powell JR, Donn KH. (1983). The Pharmacokinetic Basis for H2-Antagonist Drug Interactions: Concepts and Implications. *J Clin Gastroenterol*. 5(Suppl 1):95-113. [PubMed 6140286]
- Prastiwi, Y. R. (2021). *Profil Pengobatan Warfarin pada Pasien Rawat Inap di Rumah Sakit Akademik (RSA) Universitas Gadjah Mada*. Univeristas Gadjah Mada.
- Putriana, N. A., Rusdiana, T., Rostinawati, T., Akbar, M. R., & Destiani, D. P. (2022). Evaluation of Adverse Drug Reaction in Patients Warfarin Therapy. *Journal of Advanced Pharmaceutical Technology and Research*, 13(4), 291–295. https://doi.org/10.4103/japtr.japtr_439_22

- Rahmawati, F., Aulia, I. A. A., & Pramantara, I. D. P. (2022). Profil Klinis Pasien Pengguna Warfarin pada Poli Jantung RSUD Dr. Soeselo Kabupaten Tegal. *Majalah Farmaseutik*, 18(2), 201–210. <https://doi.org/10.22146/farmaseutik.v1i1.62470>
- Rahmawati, D.U. dan Mutmainah, N, 2021, Kajian Interaksi Obat Potensial pada Pasien Penyakit Jantung Koroner Rawat Inap di RSUD Moewardi Tahun 2018. *University Research Clloquium*. 417-428.
- Raru, Y., Abouzid, M., Zeid, F., & Teka, S. (2019). Pulmonary Vein Thrombosis Secondary to Tuberculosis in A Non-HIV Infected Patient. *Respiratory Medicine Case Reports*, 26, 91–93. <https://doi.org/10.1016/j.rmcr.2018.11.020>
- Rey AM, Gums JG. (1991). Altered Absorption of Digoxin, Sustained-Release Quinidine, and Warfarin with Sucralfate Absorption. *DICP*. 25(7-8):745-746. [PubMed 1949932]
- Romero, J. R., & Wolf, P. A. (2013). Epidemiology of Stroke: Legacy of The Framingham Heart Study. Dalam *Global Heart* (Vol. 8, Nomor 1, hlm. 67–75). Elsevier. <https://doi.org/10.1016/j.ghheart.2012.12.007>
- Sara, N.R., 2017, Profil Nilai International Normalized Ratio (INR) pada Pasien Stroke Iskemik di Rumah Sakit Umum Daerah dr. Zainoel Abidin Banda Aceh, Fakultas Kedokteran Universitas Syiah Kuala Darussalam Banda Aceh.
- Sellers EM, Koch-Weser J. (1970). Displacement of Warfarin from Human Albumin by Diazoxide and Ethacrynic, Mefenamic, and Nalidixic Acids. *Clin Pharmacol Ther*. 11(4):524-529. [PubMed 5429179]
- Scott, A., Park, B., & Breckenridge, A. (1984). Interaction between Warfarin and Propranolol. *British Journal of Clinical Pharmacology*, 17(5), 559–564. <https://doi.org/10.1111/j.1365-2125.1984.tb02390.x>
- Shalansky, S., Lynd, L., Richardson, K., Ingaszewski, A., & Kerr, C. (2007). Risk of Warfarin-Related Bleeding Events and Supratherapeutic International Normalized Ratios Associated with Complementary and Alternative Medicine: A Longitudinal Analysis. *Pharmacotherapy*, 27(9 I), 1237–1247. <https://doi.org/10.1592/phco.27.9.1237>
- Shikdar, S., Rishik, V., & Priyanka, T. B. (2024). International Normalized Ratio (INR). <https://www.ncbi.nlm.nih.gov/books/NBK507707/>
- Sonuga, B. O., Hellenberg, D. A., Cupido, C. S., & Jaeger, C. (2021). Profile and Anticoagulation Outcomes of Patients on Warfarin Therapy in An Urban Hospital in Cape Town, South Africa. *African Journal of Primary Health Care and Family Medicine*, 8(1). <https://doi.org/10.4102/phcfm.v8i1.1032>

- Stage, T. B., Pottegård, A., Henriksen, D. P., Christensen, M. M. H., Højlund, K., Brøsen, K., & Damkier, P. (2016). Initiation of Glucose-Lowering Treatment Decreases International Normalized Ratio Levels among Users of Vitamin K Antagonists: A Self-Controlled Register Study. *Journal of Thrombosis and Haemostasis*, *14*(1), 129–133. <https://doi.org/10.1111/jth.13187>
- Sun, S., Wang, M., Su, L., Li, J., Li, H., & Gu, D. (2006). Study on Warfarin Plasma Concentration and Its Correlation with International Normalized Ratio. *Journal of Pharmaceutical and Biomedical Analysis*, *42*(2), 218–222. <https://doi.org/10.1016/j.jpba.2006.03.019>
- Swarjana, I. K. (2016). *Metodologi Penelitian Kesehatan*, Penerbit ANDI, Yogyakarta.
- Tamam, B. M. (2016). *13 Faktor dan Mekanisme Pembekuan Darah Pada Manusia*. Generasi Biologi. <https://generasibiologi.com/2016/10/13-faktor-mekanisme-pembekuan-darah.html>
- Tambunan, K. L., Kurnianda, J., Suharti, C., Wardhani, S. O., Sukrisman, L., Sutandyo, N., Made Rena, N. R., Acang, N., Benyamin, A. F., Prenggono, M. D., Gatot, D., Fadjari, T. H., & Pandelaki, J. (2020). IDENTIA Registry: Incidence of Deep Vein Thrombosis in Medically Ill Subjects at High Risk in Indonesia: A Prospective Study. *Acta Med Indones*, *52*, 14–24.
- Tomaselli, G. F., Mahaffey, K. W., Cuker, A., Dobesh, P. P., Doherty, J. U., Eikelboom, J. W., Florido, R., Gluckman, T. J., Hucker, W. J., Mehran, R., Messé, S. R., Perino, A. C., Rodriguez, F., Sarode, R., Siegal, D. M., & Wiggins, B. S., 2020, 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee, *Journal of the American College of Cardiology*, *76* (5), 594–622. <https://doi.org/10.1016/j.jacc.2020.04.053>
- Thijssen, H. H. W., Soute, B. A., Vervoort, L. M., & Claessens, J. G. (2004). Paracetamol (Acetaminophen) Warfarin Interaction: NAPQI, The Toxic Metabolite of Paracetamol, is An Inhibitor of Enzymes in The Vitamin K Cycle. *Thrombosis And Haemostasis*, *92*(4), 797–802. <https://doi.org/10.1160/TH04-02-0109>
- Tideman, P. A., Tirimacco, R., St John, A., & Roberts, G. W. (2015). Correction: How to Manage Warfarin Therapy. *Australian Prescriber*, *39*(2). <https://doi.org/10.18773/austprescr.2016.027>
- Tomaselli, G. F., Mahaffey, K. W., Cuker, A., Dobesh, P. P., Doherty, J. U., Eikelboom, J. W., Florido, R., Gluckman, T. J., Hucker, W. J., Mehran, R., Messé, S. R., Perino, A. C., Rodriguez, F., Sarode, R., Siegal, D. M., & Wiggins, B. S. (2020). 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set

- Oversight Committee. *Journal of the American College of Cardiology*, 76(5), 594–622. <https://doi.org/10.1016/j.jacc.2020.04.053>
- Turpie, A. G. G., Gent, M., Laupacis, A., Yves Latour, M. D., & Gunstensen, J. (1993). A Comparison of Aspirin with Placebo in Patients Treated with Warfarin after Heart-Valve Replacement. *The New England Journal of Medicine*. <https://doi.org/10.1056/NEJM199308193290802>
- Washington, C., Hou, S. Y. E., Hughes, N. C., Campanella, C., & Berner, B. (2007). Ciprofloxacin Prolonged-Release Tablets Do Not Affect Warfarin Pharmacokinetics and Pharmacodynamics. *Journal of Clinical Pharmacology*, 47(10), 1320–1326. <https://doi.org/10.1177/0091270007305504>
- Weibert RT, Lorentz SM, Townsend RJ, et al. (1989). Effect of Erythromycin in Patients Receiving Long-Term Warfarin Therapy. *Clin Pharm*. 8:210-214. [PubMed 2706893]
- Wood TC, Johnson KL, Naylor S, Weinshilboum RM. (2002). Cefazolin Administration and 2 Methyl-1,3,4-Thiadiazole-5-Thiol in Human Tissue: Possible Relationship to Hypoprothrombinemia. *Drug Metab Dispos*. 30 (10):1123-1128. [PubMed 12228189]
- Xue, L., Zhang, Y., Xie, C., Zhou, L., Liu, L., Zhang, H., Xu, L., Song, H., Lin, M., Qiu, H., Zhu, J., Zhu, Y., Zou, J., Zhuang, W., Xuan, B., Chen, Y., Fan, Y., Wu, D., Shen, Z., & Miao, L. (2019). Relationship Between Warfarin Dosage and International Normalized Ratio: A Dose–Response Analysis and Evaluation Based on Multicenter Data. *European Journal of Clinical Pharmacology*, 75(6), 785–794. <https://doi.org/10.1007/s00228-019-02655-8>
- Yamagishi, S. I. (2019). Concerns about Clinical Efficacy and Safety of Warfarin in Diabetic Patients with Atrial Fibrillation. Dalam *Cardiovascular Diabetology* (Vol. 18, Nomor 1). BioMed Central Ltd. <https://doi.org/10.1186/s12933-019-0818-0>
- Yang CS, Boswell R, Bungard TJ. (2021). A Case Series of The Rifampin-Warfarin Drug Interaction: Focus on Practical Warfarin Management. *Eur J Clin Pharmacol*. 77 (3):341-348. [PubMed 33409685]
- Yang, F., Hellyer, J. A., Than, C., Ullal, A. J., Kaiser, D. W., Heidenreich, P. A., Hoang, D. D., Winkelmayr, W. C., Schmitt, S., Frayne, S. M., Phibbs, C. S., & Turakhia, M. P. (2017). Warfarin Utilisation and Anticoagulation Control in Patients with Atrial Fibrillation and Chronic Kidney Disease. *Heart*, 103(11), 818–826. <https://doi.org/10.1136/heartjnl-2016-309266>
- Yeh, J.J., Lin, C.L. and Kao, C.H. (2019). Relationship between Pneumonia and Cardiovascular Diseases: A Retrospective Cohort Study of The General Population. *European journal of internal medicine*, 59, pp.39-45.